Mpex Pharmaceuticals Names Mark Wiggins Chief Busine...( - Wiggins Joins from Biogen Idec - .....)

- Wiggins Joins from Biogen Idec -

SAN DIEGO, April 20 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that Mark Wiggins has joined the company as Chief Business Officer. Mr. Wiggins comes to Mpex from Biogen Idec, Inc. where he most recently served as Executive Vice President of Business Development, and was a member of the Executive Committee. At Mpex he will be focusing on commercial planning and business development activities related to the company's lead product, MP-376. MP-376 is an inhaled antibiotic which is being developed for use as a maintenance therapy for the prevention of exacerbations in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD).

During his 11 years at Biogen Idec and its predecessor Idec Pharmaceuticals, Mr. Wiggins was involved in a wide variety of commercial and business development activities. As Vice President of Marketing and Business Development at Idec he was responsible for all aspects of marketing and reimbursement. He was also a member of the management committee for the collaboration with Genentech on Rituxan(R), a drug generating multi-billions of dollars annually and used for treating a number of cancer and autoimmune indications. As global head of business development for Biogen Idec, Mr. Wiggins and his team completed three acquisitions and more than 20 licensing/partnering transactions. Prior to his time with Biogen Idec, Mr. Wiggins held a number of senior positions in marketing and business development for Hybridon, Schering-Plough, Johnson&Johnson and Pfizer. Mr. Wiggins received his B.S. degree in finance from Syracuse University and an MBA from the University of Arizona.

"Mark's background in the industry spearheading highly successful deals and partnerships is impressive and we are delighted to have him join Mpex," said Daniel Burgess, President and Chief Executive Officer of Mpex P
'/>"/>